(Q36643696)

15 August 2017

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

3

Rosemarie Mick

1 reference

15 August 2017

Robert H Vonderheide

1

1 reference

15 August 2017

Jennifer M Burg

2

1 reference

15 August 2017

Jennifer A Trosko

4

1 reference

15 August 2017

Dongguang Li

5

1 reference

15 August 2017

M Naveed Shaik

6

1 reference

15 August 2017

Anthony W Tolcher

7

1 reference

15 August 2017

Omid Hamid

8

1 reference

15 August 2017

1 January 2013

1 reference

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

1

1 reference

15 August 2017

e23033

1 reference

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Prospect of targeting the CD40 pathway for cancer therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Role for CD40-CD40 ligand interactions in the immune response to solid tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Phase II study of paclitaxel and carboplatin for malignant melanoma

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583942

Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance

20 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23483678

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23483678

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/ONCI.23033

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

23483678

1 reference